MCHP
Microchip Technology Incorporated
MCHP's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over MCHP overall, supported by stronger valuation and stronger fundamentals.
MCHP Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Stable |
MCHP's revenue, profitability and cash flow are currently strong, and its balance sheet is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
MCHP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $62.08 | — |
| Cheap | 21x | $28.42 | -54% |
| Fair | 40x | $53.17 | -14% |
| Current | 47x | $62.08 | — |
| Expensive | 104x | $138 | +122% |
Historical ranges are pointers, not guarantees.
MCHP's PE is in its fair range at 47x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over MCHP in the historical PE scenario, which offers more potential upside but is not a forecast.
MCHP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
MCHP has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
MCHP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.02 | +202% |
| Q3 2026 | $1.33 | +$1.78 |
| Q2 2026 | $0.68 | +$1.02 |
| Q1 2026 | $0.22 | +$0.23 |
| Q4 2025 | -$0.29 | -151% |
| Q3 2025 | -$0.45 | -131% |
| Q2 2025 | -$0.34 | -114% |
| Q1 2025 | -$0.01 | -100% |
| Q4 2024 | $0.57 | -87% |
MCHP has returned to profit: it earned $1.33 per share over the past year, after losing money the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over MCHP on earnings, with more consistent year-over-year improvement.
MCHP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +42% |
| Q2 2026 | $1.5B | +38% |
| Q1 2026 | $1.3B | +35% |
| Q4 2025 | $1.2B | +16% |
| Q3 2025 | $1.1B | -2% |
| Q2 2025 | $1.1B | -13% |
| Q1 2025 | $970.5M | -27% |
| Q4 2024 | $1B | -42% |
MCHP's revenue is recovering but still below its 2023 peak: $1.6B last quarter, up 42% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 29% | +21 points |
| Q2 2026 | 23% | +20 points |
| Q1 2026 | 17% | +27 points |
| Q4 2025 | 13% | +9.8 points |
| Q3 2025 | 7.8% | -4.8 points |
| Q2 2025 | 3% | -15 points |
| Q1 2025 | -10% | -30 points |
| Q4 2024 | 3% | -27 points |
MCHP's operating margin was 29% last quarter, up 21 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over MCHP on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over MCHP on profitability, with a higher operating margin.
MCHP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $396.1M | +668% |
| Q2 2026 | $497.6M | +93% |
| Q1 2026 | $242.8M | +27% |
| Q4 2025 | $318.9M | +26% |
| Q3 2025 | $51.6M | +126% |
| Q2 2025 | $257.7M | -15% |
| Q1 2025 | $191.7M | -51% |
| Q4 2024 | $253.4M | -68% |
MCHP's free cash flow has been positive every quarter for seven years: $1.5B over the past year, up 93% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over MCHP on cash flow, with more consistent year-over-year improvement.
MCHP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +100K shares |
| 1 year | +1% | +5.6M shares |
| 3 years | +0.3% | +1.4M shares |
| 5 years | -2.7% | -15.3M shares |
| Available history | +6.6% | +34M shares |
MCHP has 551M diluted shares, up 1% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $6.5M |
| Q3 2024 | $17.3M |
| Q2 2024 | $72.7M |
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over MCHP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
MCHP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.8x | Moderate |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 4.5x | High |
| Q4 2025 | 5.9x | High |
| Q3 2025 | 6.7x | High |
| Q2 2025 | 5.8x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.3x | High |
MCHP's net debt is about 2.8 years of its operating earnings (EBITDA), down from 6.7 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over MCHP on leverage, with a lower net debt burden relative to earnings.
MCHP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 28.2 | Neutral |
MCHP's weekly RSI is 39 (neutral) and its Stochastic is 28 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
MCHP PE vs Technology Sector
| Metric | MCHP | Sector median | Relative |
|---|---|---|---|
| PE | 47x | 28x | 68% above |
| PE % | 61 | 35 | 26 pts above |
MCHP is trading at 47x earnings, a 68% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over MCHP on valuation relative to its sector.
MCHP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.7 | 15% below |
| 20 week MA | $76.2 | 18% below |
| 50 week MA | $77.2 | 20% below |
| 100 week MA | $68.2 | 9% below |
| 200 week MA | $75.2 | 17% below |
MCHP is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over MCHP on trend strength, trading above more of its moving averages.
MCHP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.7 | $68.4 | +30% |
| 2021 | $68.4 | $86.9 | +27% |
| 2022 | $86.9 | $69.9 | -20% |
| 2023 | $69.9 | $90.2 | +29% |
| 2024 | $90.2 | $58.3 | -35% |
| 2025 | $58.3 | $64.9 | +11% |
| 2026 YTD | $64.9 | $62.1 | -4.4% |
MCHP has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.